Innov Clin Neurosci. 2026;23(1–3):5–9.

Dear Editor:

Selective serotonin reuptake inhibitors (SSRIs) have long been a cornerstone in the treatment of mood disorders, particularly depression and anxiety. Since their introduction in the late 1980s, SSRIs have revolutionized psychiatric care by offering a safer alternative to older classes of antidepressants with fewer adverse effects. However, despite their widespread use and proven efficacy, SSRIs are not without their drawbacks, one of which is sexual dysfunction, both during treatment and after discontinuation.1 This persistent sexual dysfunction, which can continue long after stopping the medication, is becoming increasingly recognized as a significant and distressing component of post-SSRI sexual dysfunction (PSSD).

PSSD refers to a collection of symptoms that some individuals experience following the discontinuation or reduction in dosage of SSRI medications. The syndrome typically includes a range of physical, emotional, and cognitive disturbances, such as brain fog, fatigue, insomnia, dizziness, anxiety, and sensory and cognitive disturbance. While these symptoms are well-documented, sexual dysfunction remains one of the most challenging and persistent aspects of PSSD.1,2 Even after stopping SSRI treatment, many individuals report enduring sexual difficulties, such as diminished libido, erectile dysfunction, and difficulty achieving orgasm. For these individuals, the lasting sexual side effects represent a severe impairment of quality of life, and they can cause significant emotional distress, relationship issues, and reluctance to seek further treatment. Sexual dysfunction during SSRI treatment is a well-known adverse effect, affecting a substantial proportion of patients. These issues typically manifest as decreased libido, anorgasmia, delayed ejaculation, or erectile dysfunction. Although these adverse effects are expected to resolve upon discontinuation of the medication, patients with PSSD often report continued sexual difficulties long after stopping their SSRI regimen. This lingering dysfunction may include reduced sexual desire, persistent erectile issues, or difficulties achieving orgasm, all of which can have profound impacts on personal relationships and emotional wellbeing.3

The mechanisms behind PSSD remain unclear, but researchers speculate that they are linked to long-term changes in the brain’s serotonin system. SSRIs work by increasing serotonin levels in the brain, which is thought to enhance mood and alleviate symptoms of depression and anxiety. However, serotonin plays a critical role in regulating sexual behavior, and prolonged exposure to high levels of serotonin can interfere with sexual function. As the brain adjusts to the heightened serotonin levels during SSRI treatment, it may decrease the sensitivity or number of serotonin receptors. When the medication is stopped, the brain may struggle to return to its pretreatment state, leading to ongoing sexual dysfunction.3

This disruption in the serotonin system, particularly the alteration of serotonin receptor sensitivity, could be a major factor in the persistence of sexual dysfunction in this enduring and disabling syndrome. While serotonin is essential for regulating sexual arousal and satisfaction, the imbalance in the brain dopamine/serotonin ratio caused by SSRI discontinuation could result in a continued sexual deficit.1–3 Additionally, this dysfunction can be exacerbated by the psychological effects of PSSD, as patients may experience anxiety, depression, and frustration, all of which further impact sexual desire and performance.

Currently, there is no standard treatment protocol specifically for PSSD, and patients often face a lack of understanding from healthcare providers. Since PSSD is not universally recognized as a formal medical diagnosis, many physicians are unsure of how to approach treatment.4,5 Furthermore, sexual dysfunction is often an overlooked and underreported side effect of SSRI discontinuation, leaving many patients feeling isolated and unsure where to turn for help.

The treatment of PSSD presents significant challenges due to the condition’s heterogeneous nature. The severity and duration of sexual side effects vary widely between individuals, and there is no universally effective solution.3–5 Some patients may find that their sexual function gradually improves with time, while others report persistent issues that do not resolve after months or even years. In the absence of well-established treatment guidelines, management strategies often involve a combination of approaches, including pharmacological treatments, therapy, and lifestyle changes.6

For some individuals, switching to a different class of antidepressant (eg, vortioxetine, bupropion, or desvenlafaxine) or using adjunct medications, such as bupropion and mirtazapine, which have a lower incidence of sexual side effects, may help alleviate sexual dysfunction. Other patients may benefit from medications specifically designed to address sexual dysfunction, such as sildenafil or tadalafil, which may help with erectile issues. However, these treatments are not always effective for all patients, and the adverse effects may not fully resolve the sexual difficulties.5,6 Notably, much of the existing literature on pharmacological management of iatrogenic sexual dysfunction has predominantly focused on male patients, particularly in relation to erectile dysfunction.

Psychotherapy, particularly cognitive-behavioral therapy, can also play a vital role in managing PSSD. Therapy can help individuals address the emotional and psychological aspects of sexual dysfunction, including the anxiety or depression that may exacerbate the issue. In addition, couples therapy may be helpful for partners who are experiencing relationship strain due to sexual difficulties, providing a supportive environment to discuss and address the issue.

Looking toward the future, the treatment of PSSD is likely to improve as research into the condition continues. While much remains unknown, several promising areas of investigation could lead to more effective therapies. One potential avenue for future treatment is the development of medications that target specific serotonin receptors or pathways to rebalance serotonin signaling. These therapies may offer a more tailored approach to treatment, potentially reducing the sexual side effects associated with SSRIs and improving outcomes for those with PSSD. Moreover, emerging research on neuroplasticity suggests that techniques such as transcranial magnetic stimulation and focal muscle vibration6 could offer novel ways to stimulate changes in brain function and restore neurotransmitter balance. These therapies, which are already being explored for other neuropsychiatric conditions, could hold promise for alleviating the lingering sexual dysfunction seen in PSSD.

Personalized medicine, guided by genetic and biomarker data, may also provide a more targeted approach to treating sexual dysfunction in individuals with PSSD. By understanding how a patient’s unique genetic makeup influences their response to SSRIs and other medications, healthcare providers may be able to develop more precise treatment strategies, minimizing sexual side effects while effectively managing mood disorders.7

Public awareness of PSSD is crucial in improving outcomes for affected individuals. As more patients and healthcare professionals recognize the reality of PSSD and its impact on sexual health, there may be increased advocacy for research funding, improved diagnostic criteria, and better treatment options.

PSSD represents a significant and frequently underrecognized consequence of SSRI use and cessation. While SSRIs remain a cornerstone in the treatment of mood disorders, the persistent sexual side effects tied to PSSD pose a considerable challenge for both patients and healthcare providers. Ongoing research into the mechanisms of PSSD and its management holds promise for future treatments that could alleviate the burden of this debilitating condition. In the meantime, it is crucial for patients to advocate for their health, while the medical community must intensify research efforts to deepen our understanding and develop more effective solutions for PSSD.

With regards,

Rocco Salvatore Calabrò, MD, PhD

Dr. Calabrò is with the Neurorehabilitation Unit at IRCCS Centro Neurolesi “Bonino-Pulego,” Messina, Italy.

Funding/financial disclosures. Dr. Calabrò has no relevant conflicts of interest. No funding was received for the preparation of this letter.

Correspondence. Rocco Salvatore Calabrò, MD, PhD;

References

  1. Marks S. A clinical review of antidepressants, their sexual side-effects, post-SSRI sexual dysfunction, and serotonin syndrome. Br J Nurs. 2023;32(14):678–682.
  2. Peleg LC, Rabinovitch D, Lavie Y, et al. Post-SSRI sexual dysfunction (PSSD): biological plausibility, symptoms, diagnosis, and presumed risk factors. Sex Med Rev. 2022;10(1):91–98.
  3. Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction? Sex Med Rev. 2018;6(2):217–223.
  4. Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022;33(1):65–76.
  5. Ben-Sheetrit J, Hermon Y, Birkenfeld S, et al. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry. 2023;22(1):15.
  6. De Luca R, Bonanno M, Manuli A, Calabrò RS. Cutting the first turf to heal post-SSRI sexual dysfunction: a male retrospective cohort study. Medicines (Basel). 2022;9(9):45.
  7. Studt A, Gannon M, Orzel J, et al. Characterizing post-SSRI sexual dysfunction and its impact on quality of life through an international online survey. Int J Risk Saf Med. 2021;32(4):321–329.